BMS & AstraZeneca begin phase-4 trial of Saxgliptin in type-2 diabetes with cardio risk factors
Thursday, March 11, 2010 13:00 IST Princeton, New Jersey
Bristol-Myers Squibb Company and AstraZeneca announced the commencement of the "Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus" trial (SAVOR-TIMI 53)